Fig. 1.
White blood cell count (WBC), blood transfusion requirement, and spleen enlargement during ruxolitinib-hydroxyurea treatment.

White blood cell count (WBC), blood transfusion requirement, and spleen enlargement during ruxolitinib-hydroxyurea treatment.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal